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PEfficacy and Safety of Enoxaparin Versus
Unfractionated Heparin in Patients With ST-Segment
Elevation Myocardial Infarction Also Treated With Clopidogrel
Marc S. Sabatine, MD, MPH, FACC,* David A. Morrow, MD, MPH, FACC,* Anthony Dalby, MD,†
Mathias Pfisterer, MD,‡ Tibor Duris, MD,§ Jose Lopez-Sendon, MD, FACC, Sabina A. Murphy, MPH,*
Runlin Gao, MD, FACC,¶ Elliott M. Antman, MD, FACC,* Eugene Braunwald, MD, MACC,*
for the ExTRACT-TIMI 25 Investigators
Boston, Massachusetts; Johannesburg, South Africa; Basel, Switzerland; Nove Zamky, Slovakia;
Madrid, Spain; and Beijing, China
Objectives The purpose of this study was to determine the efficacy and safety of enoxaparin (ENOX) versus unfractionated
heparin (UFH) in patients with ST-segment elevation myocardial infarction (STEMI) receiving fibrinolytic therapy
with and without clopidogrel.
Background The efficacy and safety of ENOX and clopidogrel given together in STEMI remains to be defined.
Methods We compared the rates of major adverse cardiovascular events (MACE) as well as the rates of bleeding in medi-
cally managed patients randomized to ENOX versus UFH in the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis
Reperfusion for Acute Myocardial Infarction Treatment–Thrombolysis In Myocardial Infarction 25) trial, stratified
by concomitant clopidogrel use.
Results Enoxaparin significantly reduced the rate of the composite of death, recurrent myocardial infarction, myocardial
ischemia, or stroke, compared with UFH, both in patients (n  2,173) treated with clopidogrel (10.8% vs. 13.9%,
adjusted odds ratio [ORadj] 0.70, p  0.013) and in patients (n  12,918) not treated with clopidogrel (13.3%
vs. 15.3%, ORadj 0.85, p  0.003) with no evidence of heterogeneity (pinteraction  0.21). The excess risk of TIMI
major bleeding with ENOX versus UFH was numerically but not statistically significantly higher in patients treated
with clopidogrel (2.7% vs. 1.0%) versus those who were not (2.1% vs. 1.2%) (pinteraction  0.61). Net clinical ben-
efit (MACE and major bleeding) favored treatment with ENOX over UFH, either with concomitant clopidogrel
(absolute risk reduction 2.4%, 95% confidence interval [CI] 0.5% to 5.3%) or without (absolute risk reduction
1.7%, 95% CI 0.5% to 3.0%) (pinteraction  0.61).
Conclusions In patients with STEMI receiving fibrinolytic therapy, the net benefit of ENOX is similar in patients who are and
are not treated with clopidogrel. The totality of trial data suggest that the combination of a fibrinolytic, aspirin,
clopidogrel, and ENOX offers an attractive pharmacologic reperfusion strategy in STEMI. (J Am Coll Cardiol
2007;49:2256–63) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.01.092(
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June 12, 2007:2256–63 Efficacy and Safety of Enoxaparin With Clopidogrelhown in the ExTRACT-TIMI 25 (Enoxaparin and Throm-
olysis Reperfusion for Acute Myocardial Infarction Treat-
ent–Thrombolysis In Myocardial Infarction 25) trial that a
trategy of the low-molecular-weight heparin (LMWH) enox-
parin (ENOX) was superior to a strategy of UFH in prevent-
ng death or recurrent ischemic events in patients receiving
brinolytic therapy for STEMI (3). While the ExTRACT-
IMI 25 trial was enrolling subjects, 2 trials of another
djuvant therapy in STEMI, clopidogrel, were completed.
pecifically, both the CLARITY (Clopidogrel as Adjunctive
eperfusion Therapy)-TIMI 28 study (4) and COMMIT/
CS-2 study (Clopidogrel and Metoprolol in Myocardial
nfarction Trial/Second Chinese Cardiac Study) (5) demon-
trated that the addition of clopidogrel to a standard reperfu-
ion regimen including aspirin reduced the rate of both death
nd recurrent ischemic events. With these 2 recent observa-
ions, the question arose as to whether clopidogrel and ENOX
an and should be used together. Each drug significantly
educes major adverse cardiovascular events (MACE) in
TEMI; however, whether those benefits would be additive or
edundant remains to be defined. Similarly, in terms of safety,
NOX was associated with a modest but statistically signifi-
ant increase in major bleeding in the ExTRACT-TIMI 25
rial (3), and clopidogrel was associated with an increase in
Baseline Characteristics by Clopidogrel Use
Table 1 Baseline Characteristics by Clopido
Variable Clopidogrel
Baseline characteristics
Age, yrs 58 
Age 75 yrs 211 (9
Male 1,737 (7
Caucasian 1,325 (6
Weight, kg 74 
Hypertension 881 (4
Hyperlipidemia 303 (1
Current smoker 1,022 (4
Diabetes mellitus 398 (1
Prior MI 258 (1
Prior angina pectoris 520 (2
Prior PCI 91 (4
Index presentation and medications
Anterior MI 971 (4
SBP, mm Hg 133 
Heart rate, beats/min 77 
Killip class II to IV 239 (1
Creatinine clearance, ml/min 80 (6
Time from symptom onset to start of
fibrinolytic, h
3.3 
Fibrin-specific lytic 1,759 (8
Randomized allocation to ENOX 1,083 (4
Beta-blocker 1,833 (8
ACE inhibitor or ARB 1,771 (8
Statin 1,757 (8
Data are presented as mean  SD for continuous variables, median (
(%) for dichotomous variables. Denominators are based on availableACE angiotensin converting enzyme; ARB angiotensin receptor blocker;
coronary intervention; SBP  systolic blood pressure.inor bleeding in the COMMIT/
CS-2 trial (5); such an increase
n bleeding with clopidogrel was
ot seen in the CLARITY-TIMI
8 trial (4), which did not enroll
atients 75 years of age. Neither
lopidogrel nor ENOX was asso-
iated with an excess of intracra-
ial hemorrhage (ICH) when each
rug was analyzed in isolation. To
valuate the impact of combining
NOX and clopidogrel, we ana-
yzed the efficacy and safety profile
f ENOX compared with UFH in
edically-treated patients who did
nd did not receive concomitant
lopidogrel in the ExTRACT-
IMI 25 trial.
ethods
atient population and procedures. The design of the
xTRACT-TIMI 25 trial has been reported (6). In brief,
he intention-to-treat cohort consisted of 20,479 patients
Use
,173) No Clopidogrel (n  12,918) p Value
61  12 0.001
1,848 (14.3) 0.001
9,555 (74.0) 0.001
12,107 (93.7) 0.001
78  14 0.001
5,964 (46.8) 0.001
1,504 (15.9) 0.008
5,976 (46.3) 0.51
1,793 (14.1) 0.001
1,763 (13.7) 0.025
3,983 (31.0) 0.001
234 (1.8) 0.001
5,765 (45.0) 0.94
134  20 0.10
77  17 0.50
1,568 (12.1) 0.13
) 80 (62–104) 0.22
3.4  1.4 0.13
10,309 (79.8) 0.22
6,528 (50.5) 0.55
11,111 (86.0) 0.04
10,240 (79.3) 0.02
7,969 (61.7) 0.001
artile range) for non-normally distributed continuous variables, and n
each characteristic.
Abbreviations
and Acronyms
ENOX  enoxaparin
ICH  intracranial
hemorrhage
LMWH  low-molecular-
weight heparin
MACE  major adverse
cardiovascular event
MI  myocardial infarction
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
UFH  unfractionated
heparingrel
(n  2
12
.7)
9.9)
1.0)
15
1.0)
8.5)
7.1)
8.5)
1.9)
4.1)
.2)
5.1)
21
16
1.0)
2–101
1.8
1.0)
9.8)
4.4)
1.5)
0.9)
interqu
data forENOX enoxaparin; MImyocardial infarction; PCI percutaneous
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Efficacy and Safety of Enoxaparin With Clopidogrel June 12, 2007:2256–63t least 18 years of age presenting within 6 h of onset of
TEMI and scheduled to undergo fibrinolysis who were
andomized to receive ENOX or UFH. Patients with
ontraindications to fibrinolytic therapy, cardiogenic shock,
r renal insufficiency (serum creatinine 2.5 mg/dl for men
nd 2.0 mg/dl for women) and those who had received
MWH within the prior 8 h were excluded. The study
rotocol was approved by the relevant institutional review
oards, and informed consent was obtained from all
atients.
Study medication was administered in a double-blind
ashion with a double-dummy design. The doses and
egimens of ENOX and UFH employed have been de-
cribed in detail (3,6). For this analysis, patients who did not
eceive a fibrinolytic or did not receive aspirin at presenta-
ion were excluded. Clopidogrel could be given at the
iscretion of the treating physician. Patients were classified
s having received clopidogrel if they were given clopidogrel
uring study drug administration. To study patients who
eceived clopidogrel as part of their medical, pharmacologic
eperfusion therapy, for the primary analysis in this substudy
e excluded patients who underwent percutaneous coronary
ntervention (PCI). However, a further safety analysis was
erformed in which we analyzed the rates of bleeding in
atients who did undergo PCI during the index hospital
tay.
utcomes. Efficacy outcomes included the composite of
Figure 1 Proportion of Patients Receiving
Clopidogrel in Different Geographic Regions
Regions are based on the United Nations Statistics Geographic Region Codes.
North America and Western and Northern Europe includes Austria, Belgium,
Canada, Estonia, Finland, France, Germany, Ireland, Latvia, Lithuania, the Neth-
erlands, Norway, Sweden, Switzerland, United Kingdom, and the U.S. Eastern
and Southern Europe includes Belarus, Bulgaria, Croatia, Greece, Hungary,
Italy, Poland, Portugal, Romania, Russia, Slovakia, Spain, and Ukraine. Latin
America includes Argentina, Brazil, Chile, Mexico, and Uruguay. Middle East
and Africa includes Israel, Jordan, Lebanon, South Africa, and Turkey. Asia and
Australasia includes Australia, China, Hong Kong, India, Republic of Korea,
Malaysia, New Zealand, Singapore, and Thailand. p  0.001 for global chi-
square as well as for all pairwise comparisons except for the rates in Latin
America versus the Middle East and Africa.eath, nonfatal recurrent myocardial infarction (MI), non-atal recurrent severe myocardial ischemia (ischemic dis-
omfort at rest 10 min accompanied by new, horizontal,
r downsloping ST-segment depression), or nonfatal stroke
hrough 30 days as well as the individual components (6).
afety outcomes included TIMI major bleeding (fatal or
onfatal) (7), ICH (fatal or nonfatal), and TIMI minor
leeding through 30 days. Events were adjudicated by an
ndependent clinical events committee that was blinded to
reatment assignment.
tatistical analysis. The characteristics of patients who
ere and were not treated by their physician with clopi-
ogrel as well as of those who were randomized to ENOX
ersus UFH within each clopidogrel use subgroup were
ompared with t tests for continuous variables, Wilson rank
um tests for non-normally distributed continuous variables,
nd chi-square tests for categorical variables. Adjusted odds
atios (ORadj) and 95% confidence intervals (CIs) were
alculated in multivariable logistic regression models that
djusted for the components of the TIMI risk score for
TEMI (age, diabetes mellitus, hypertension, previous an-
ina, systolic blood pressure, heart rate, Killip class, weight,
nterior MI, left bundle branch block, and time to fibrino-
ytic therapy) (8) to quantify the unconfounded effect of
NOX versus UFH on the incidence of the efficacy and
afety outcomes; analyses were conducted separately in
atients who were and were not were treated with clopi-
ogrel. Per the main trial’s statistical analysis plan, efficacy
nalyses were performed in the intent-to-treat population
nd safety analyses were performed in the as-treated popu-
ation. Tests for interaction between clopidogrel, study
Figure 2 Proportion of Patients Receiving
Clopidogrel as a Function of Date of Enrollment
The first quarter of 2003 also includes a small number of patients (n  42)
enrolled in the last quarter of 2002 (when the trial started enrollment), and the
third quarter of 2005 also includes a small number of patients (n  7) enrolled in
the fourth quarter of 2005 (when the trial completed enrollment). CLARITY-TIMI
28  Clopidogrel as Adjunctive Reperfusion Therapy–Thrombolysis in Myocar-
dial Infarction 28 trial; COMMIT/CCS-2  Clopidogrel and Metoprolol in Myocar-
dial Infarction Trial/Second Chinese Cardiac Study.
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June 12, 2007:2256–63 Efficacy and Safety of Enoxaparin With Clopidogreledication, and outcomes were performed with logistic
egression models that included terms for randomized
reatment assignment, clopidogrel use, and randomized
reatment  clopidogrel use.
esults
mong patients who received a fibrinolytic and aspirin on
resentation and who did not undergo PCI during the index
ospital stay, a total of 2,173 were treated with clopidogrel
nd 12,918 were not. The baseline characteristics of the 2
roups are shown in Table 1. Patients who received clopi-
ogrel were younger, more likely to be male, and less likely
o be Caucasian. They were also less likely to have hyper-
ension and more likely to have hyperlipidemia or diabetes
ellitus. Patients treated with clopidogrel were less likely to
ave prior angina pectoris or a previous MI but more likely
o have had a previous PCI, although the rates of the latter
ere low (5%) in both groups. There were no significant
ifferences in the time from symptom onset to the start of
brinolytic therapy, MI location, vital signs, Killip class, or
reatinine clearance between patients who did and who did
ot receive clopidogrel. Randomization to ENOX and use
f fibrin-specific lytics did not differ between the 2 groups.
se of beta-blockers and of angiotensin-converting enzyme
aseline Characteristics by Treatment Group Within Clopidogrel Co
Table 2 Baseline Characteristics by Treatment Group Within C
Variable
Clopidogre
ENOX
(n  1,083) (n
Baseline characteristics
Age, yrs 58  12
Age 75 yrs 113 (10.4) 9
Male 856 (79.0) 88
Caucasian 660 (60.9) 66
Weight, kg 74  14
Hypertension 436 (40.9) 44
Hyperlipidemia 149 (18.3) 15
Current smoker 492 (45.4) 53
Diabetes mellitus 192 (17.8) 20
Prior MI 132 (12.3) 12
Prior angina pectoris 251 (23.4) 26
Prior PCI 43 (4.0) 4
Index presentation and medications
Anterior MI 478 (44.6) 49
SBP, mm Hg 133  21 1
Heart rate, beats/min 77  17
Killip class II to IV 114 (10.5) 12
Creatinine clearance, ml/min 80 (61–101) 8
Time from symptom onset to start of fibrinolytic, h 3.3  2.2
Fibrin-specific lytic 879 (81.2) 88
Beta-blocker 921 (85.0) 91
ACE inhibitor or ARB 881 (81.4) 89
Statin 860 (79.4) 89
ata are presented as mean  SD for continuous variables, median (interquartile range) for non-n
n available data for each characteristic.
UFH  unfractionated heparin; other abbreviations as in Table 1.nhibitors or angiotensin receptor blockers was high (ap- iroximately 80%) in both groups. Patients who were treated
ith clopidogrel were more likely to receive a statin.
The proportion of patients who received clopidogrel
aried by geographic region (Fig. 1), and was highest among
atients enrolled in Asia and Australasia (54.5%), high in
orth America and Western and Northern Europe
21.4%), intermediate in Latin America (12.7%) and the
iddle East and Africa (14.0%), and lowest in Eastern and
outhern Europe (7.5%) (p 0.001 for global chi-square as
ell as for all pairwise comparisons except for the rates in
atin America vs. the Middle East and Africa). Use of
lopidogrel as part of the adjuvant medical therapy also
ncreased over time (Fig. 2), starting at approximately 7.5%
t the beginning of the trial and quadrupling to 30% by the
nd of the trial (p  0.001 for trend over time). The rate of
lopidogrel use nearly doubled in the 6 months after March
005, when the results of the CLARITY-TIMI 28 and
OMMIT/CCS-2 studies were presented.
As was the case in the overall trial, there were no clinically
ignificant differences in the baseline characteristics or index
resentation and treatments between patients randomized
o ENOX versus UFH, in either the clopidogrel or the no
lopidogrel cohorts (Table 2).
Enoxaparin significantly reduced the rate of the compos-
grel Cohorts
2,173) No Clopidogrel (n  12,918)
090) p Value
ENOX
(n  6,528)
UFH
(n  6,390) p Value
12 0.72 61  12 61  12 0.05
) 0.26 891 (13.7) 957 (15.0) 0.03
8) 0.30 4,837 (74.1) 4,718 (73.8) 0.73
0) 0.97 6,108 (93.6) 5,999 (93.9) 0.48
15 0.69 78  15 78  14 0.04
1) 0.93 3,025 (46.9) 2,939 (46.6) 0.70
7) 0.81 789 (16.5) 715 (15.3) 0.10
7) 0.13 3,035 (46.5) 2,941 (46.1) 0.62
1) 0.42 925 (14.4) 868 (13.8) 0.33
6) 0.63 895 (13.8) 868 (13.6) 0.81
8) 0.45 2,017 (31.1) 1,966 (30.9) 0.83
) 0.62 129 (2.0) 105 (1.6) 0.16
5) 0.66 2,876 (44.4) 2,889 (45.5) 0.20
21 0.96 133  20 134  20 0.15
16 0.09 77  17 77  16 0.51
5) 0.48 804 (12.3) 764 (12.0) 0.53
103) 0.39 82 (63–105) 80 (62–103) 0.01
1.4 0.58 3.4  1.4 3.4  1.4 0.78
7) 0.80 5,207 (79.8) 5,102 (79.8) 0.91
7) 0.38 5,626 (86.2) 5,485 (85.8) 0.57
7) 0.86 5,194 (79.6) 5,046 (79.0) 0.40
3) 0.09 4,073 (62.4) 3,896 (61.0) 0.10
y distributed continuous variables, and n (%) for dichotomous variables. Denominators are basedhorts
lopido
l (n 
UFH
 1,
58 
8 (9.0
1 (80.
5 (61.
75 
5 (41.
4 (18.
0 (48.
6 (19.
6 (11.
9 (24.
8 (4.4
3 (45.
33 
76 
5 (11.
0 (63–
3.3 
0 (80.
2 (83.
0 (81.
7 (82.
ormallte of death, recurrent MI, recurrent myocardial ischemia, or
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Efficacy and Safety of Enoxaparin With Clopidogrel June 12, 2007:2256–63troke by 30 days, both in patients treated with clopidogrel
10.8% vs. 13.9%, ORadj 0.70, 95% CI 0.53 to 0.93, p 
.013) and in patients not treated with clopidogrel (13.3%
s. 15.3%, ORadj 0.85, 95% CI 0.76 to 0.94, p  0.003)
Fig. 3), with no evidence of heterogeneity (pinteraction 
.21) (Table 3).
The rates of bleeding and intracranial hemorrhage are
hown in Table 4. The excess risk of TIMI major
leeding seen with ENOX compared with UFH was
.7% in patients who were treated with clopidogrel (2.7%
s. 1.0%, ORadj 2.45, 95% CI 1.20 to 4.99, p  0.01) and
.9% in those who were not (2.1% vs. 1.2%, ORadj 1.92,
5% CI 1.41 to 2.61, p  0.001), a difference that was
ot statistically significant (pinteraction  0.61). The ab-
olute differences in TIMI minor bleeding between the
NOX and UFH arms were modest (1%) and similar
Figure 3 Composite Efficacy Outcome
Stratified by Clopidogrel Use
Efficacy of enoxaparin over unfractionated heparin (UFH) in reducing death,
myocardial infarction (MI), recurrent ischemia, or stroke stratified by clopidogrel
use. ORadj  adjusted odds ratio.
linical Outcomes Through 30 Days
Table 3 Clinical Outcomes Through 30 Days
Outcomes Clopidogrel Use
Death, MI, myocardial ischemia, or stroke Yes 117/
No 865/
Death or MI Yes 79/
No 647/
Death Yes 68/
No 533/
Nonfatal MI Yes 11/
No 114/
Nonfatal myocardial ischemia Yes 43/
No 218/
Nonfatal stroke Yes 3/
No 46/ata are presented as n/N (%).
CI  confidence interval; ORadj  adjusted odds ratio (see Methods) for event in patients randomizedegardless of clopidogrel use. Lastly, there was no signif-
cant excess of ICH with ENOX compared with UFH in
he overall trial, and this finding held true regardless of
hether patients received concomitant clopidogrel (1.1%
s. 0.5%, ORadj 2.06, 95% CI 0.70 to 6.10) or not (1.0%
s. 0.8%, ORadj 1.45, 95% CI 0.96 to 2.20). All interac-
ion terms were nonsignificant.
We conducted an additional safety sensitivity analysis in
hich we examined the rates of major bleeding with ENOX
ersus UFH in patients who received clopidogrel and did
ndergo PCI. There were 9 TIMI major bleeds among
,016 patients in the ENOX arm (0.9%) versus 19 TIMI
ajor bleeds among 1,134 patients (1.7%) in the UFH arm
p  0.12). Among the 4,316 patients who received
lopidogrel (regardless of PCI use), there was no significant
xcess in TIMI major bleeding with ENOX (1.8%) versus
FH (1.4%) (p  0.35).
Examining both efficacy and safety (Fig. 4), for every
,000 patients on clopidogrel treated with ENOX rather
han UFH, we estimate 31 fewer patients would die or have
nonfatal MACE at the cost of 10 more patients having a
onfatal major bleed. Similarly, for every 1,000 patients not
aking clopidogrel treated with ENOX rather than UFH,
e estimate 21 fewer patients would die or have a nonfatal
ACE at the cost of 4 more patients having a nonfatal
ajor bleed. Thus, the net clinical benefit (composite of
eath, MI, myocardial ischemia, stroke, or major bleeding)
Table 5) similarly favored treatment with ENOX over
FH either with concomitant clopidogrel (absolute risk
eduction 2.4%, 95% CI 0.5% to 5.3%) or without
absolute risk reduction 1.7%, 95% CI 0.5% to 3.0%)
pinteraction  0.61).
iscussion
series of clinical trials in the late 1980s and early 1990s
elped establish the combination of aspirin, UFH, and a
brin-specific lytic as the foundation for pharmacologic
eperfusion therapy for STEMI (9–11). Over the ensuing
UFH ORadj (95% CI) pinteraction
(10.8) 152/1,090 (13.9) 0.70 (0.53–0.93) 0.21
(13.3) 979/6,390 (15.3) 0.85 (0.76–0.94)
(7.3) 85/1,090 (7.8) 0.86 (0.60–1.23) 0.68
(9.9) 764/6,390 (12.0) 0.79 (0.70–0.90)
(6.3) 58/1,090 (5.3) 1.12 (0.74–1.69) 0.18
(8.2) 607/6,390 (9.5) 0.83 (0.72–0.95)
(1.0) 27/1,090 (2.5) 0.43 (0.21–0.87) 0.18
(1.8) 157/6,390 (2.5) 0.71 (0.55–0.91)
(4.0) 63/1,090 (5.8) 0.65 (0.43–0.99) 0.08
(3.3) 228/6,390 (3.6) 0.99 (0.82–1.20)
(0.3) 10/1,090 (0.9) 0.33 (0.09–1.24) 0.14
(0.7) 52/6,390 (0.8) 0.94 (0.62–1.42)ENOX
1,083
6,528
1,083
6,528
1,083
6,528
1,083
6,528
1,083
6,528
1,083
6,528to enoxaparin versus unfractionated heparin; other abbreviations as in Tables 1 and 2.
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June 12, 2007:2256–63 Efficacy and Safety of Enoxaparin With Clopidogrelears, no major improvements were made on that regimen
1). However, we demonstrated in the CLARITY-TIMI 28
rial that the addition of the P2Y12 adenosine diphosphate
ADP) receptor blocker clopidogrel to standard fibrinolytic
egimens including aspirin in patients with STEMI signif-
cantly improved the rate of infarct-related artery patency
nd decreased ischemic complications through 30 days (4).
he benefit of clopidogrel in STEMI was also demon-
trated in the COMMIT/CCS-2 study, which reported a
ignificant mortality reduction with the use of clopidogrel in
atients with acute MI receiving pharmacologic therapy (5).
ow-molecular-weight heparin has been studied as an
lternative antithrombin to UFH in several trials. Although
he results were favorable, most trials were angiographic
tudies, and none was blinded (12). In contrast, the
xTRACT-TIMI 25 trial was nearly 3 times as large as all
f the previous trials combined and was conducted with a
afety Outcomes Through 30 Days
Table 4 Safety Outcomes Through 30 Days
Outcomes Clopidogrel Use EN
In patients who did not undergo PCI
Major bleeding (including ICH) Yes 29/1,
No 137/6,
ICH Yes 12/1,
No 68/6,
Minor bleeding Yes 18/1,
No 160/6,
Major or minor bleeding Yes 47/1,
No 293/6,
In patients who underwent PCI
Major bleeding (including ICH) Yes 9/1,
In patients regardless of PCI
Major bleeding (including ICH) Yes 38/2,
ata are presented as n/N (%). Bleeding events were categorized according to the Thrombolysis I
ICH  intracranial hemorrhage; other abbreviations as in Tables 1, 2, and 3.
Figure 4 Events Prevented or Caused by Treatment With
ENOX Rather Than UFH Stratified by Clopidogrel Use
The absolute number of events prevented (negative value) or provoked (posi-
tive value) per 1,000 patients treated with enoxaparin (ENOX) rather than
unfractionated heparin (UFH). MI  myocardial infarction.nouble-blind, double-dummy design. The ExTRACT-
IMI 25 trial thus provided a rigorous demonstration of the
uperiority of a strategy of ENOX compared with a strategy
f UFH in terms of preventing death or ischemic compli-
ations.
The simultaneous testing of adjuvant therapy with clopi-
ogrel and ENOX led to parallel advances that thereby
aised the important issue as to whether therapy with one
rug influences the efficacy and the safety of the other. We
ave previously shown that the benefit of clopidogrel in the
LARITY-TIMI 28 trial was comparable regardless of
hether it was given with UFH or LMWH (4). We also
bserved that patients treated with LMWH (predominantly
NOX) had a lower rate of cardiovascular death or MI
ompared with patients treated with UFH, even among
atients who were randomized to clopidogrel (13). How-
ver, treatment with the two heparins was not randomized
n the CLARITY-TIMI 28 trial, and although we adjusted
or propensity to receive LMWH, residual confounding
ould not be excluded. We now build upon these observa-
ions by demonstrating that randomization to treatment
ith ENOX results in a comparable reduction in the
omposite of death or ischemic complications even among
atients who were also treated with clopidogrel. In addition,
e found that the use of ENOX in patients who also
eceived a fibrinolytic, aspirin, and clopidogrel was not
ssociated with a statistically significantly higher rate of
leeding or ICH than was seen when used in patients not
reated with clopidogrel. Nonetheless, the rate of major
leeding was numerically greatest in patients who received
oth ENOX and clopidogrel. Therefore, the decision to
dminister a fibrinolytic, dual antiplatelet therapy, and
NOX should take into account an individual patient’s risk
f bleeding. Overall, patients receiving clopidogrel tended
o have a slightly larger absolute reduction in ischemic
vents but also a slightly greater absolute excess in bleeding
ith ENOX versus UFH, compared with patients who were
UFH ORadj (95% CI) pinteraction
.7) 11/1,085 (1.0) 2.45 (1.20–4.99) 0.61
.1) 79/6,369 (1.2) 1.92 (1.41–2.61)
.1) 5/1,085 (0.5) 2.06 (0.70–6.10) 0.60
.0) 49/6,369 (0.8) 1.45 (0.96–2.20)
.7) 14/1,085 (1.3) 1.42 (0.67–2.98) 0.55
.5) 102/6,369 (1.6) 1.63 (1.25–2.11)
.4) 25/1,085 (2.3) 1.89 (1.13–3.16) 0.99
.5) 176/6,369 (2.8) 1.79 (1.46–2.19)
.9) 19/1,134 (1.7) 0.50 (0.21–1.18) N/A
.8) 30/2,219 (1.4) 1.28 (0.77–2.12) N/A
ardial Infarction criteria.OX
081 (2
512 (2
081 (1
512 (1
081 (1
512 (2
081 (4
512 (4
016 (0
097 (1ot receiving clopidogrel. Thus, the net clinical benefit of
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nd were not receiving clopidogrel.
The rates of adverse cardiovascular events in the
xTRACT-TIMI 25 trial were lowest in patients who
eceived both clopidogrel and ENOX. This phenomenon
as also observed in the CLARITY-TIMI 28 trial (13).
owever, such data must be interpreted with great caution,
ecause allocation to only 1 of the 2 drugs was randomized
n each trial. Nonetheless, in each trial the benefit of the
andomized treatment was consistent regardless of the use
f the other adjuvant therapy. Thus, it seems likely that the
ombined use of both clopidogrel and ENOX will yield
dditive benefits for patients being treated with fibrinolytic
herapy for STEMI.
tudy limitations. Potential limitations of this study merit
onsideration. Use of clopidogrel was not randomized but
ather at the discretion of the treating physician and thus
ould have been influenced by patient or physician factors.
or that reason, our analyses focused on the comparison of
atients treated with ENOX versus UFH, allocation to
hich was randomized, and thus such comparisons should
e free of confounding. Furthermore, even though no
ignificant imbalances of baseline characteristics were ob-
erved between the ENOX and UFH arms within the
lopidogrel and no clopidogrel cohorts, we adjusted for
omponents of the TIMI risk score for STEMI to minimize
ny confounding. The doses and exact times of clopidogrel
dministration were not recorded. However, whether the
lopidogrel was given during administration of study med-
cation was noted. Therefore, to focus exclusively on med-
cal therapy for STEMI, we excluded patients who under-
ent PCI (who would routinely be treated with clopidogrel
fter their procedure) and only included in the clopidogrel
ohort patients who received clopidogrel during study drug
dministration. The dose of ENOX in the ExTRACT-
IMI 25 trial was modified on the basis of age and renal
unction. Moreover, the ExTRACT-TIMI 25 trial ex-
luded men with a serum creatinine2.5 mg/dl and women
ith a serum creatinine 2.0 mg/dl. Thus, we cannot
omment on the efficacy and safety of ENOX in combina-
ion with clopidogrel without dose-adjustment of ENOX
or age and in patients with severe renal insufficiency.
urthermore, the ExTRACT-TIMI 25 trial was a compar-
son of a strategy of ENOX given throughout the index
ospital stay versus UFH given for at least 48 h. Thus, any
ifferences in outcomes between the 2 strategies might
et Clinical Benefit Through 30 Days
Table 5 Net Clinical Benefit Through 30 Days
Outcome Clopidogrel Use
Death, MI, myocardial ischemia, stroke, or major bleeding Yes
No
ata are presented as n/N (%).
RR  risk ratio for event in patients randomized to enoxaparin versus unfractionated heparin; oeflect differences in the type of anticoagulant, the durationf treatment, and the likelihood of rebound after discontin-
ation. We found no statistically significant interactions in
erms of the efficacy or safety profile of ENOX compared
ith UFH. Although the number of patients analyzed in
he clopidogrel (n 2,173) and no clopidogrel (n 12,918)
ubgroups were relatively large, we cannot exclude the
ossibility of modest degrees of effect modification remain-
ng undetected, especially for uncommon events such as
leeding and ICH. A very large 2  2 factorial design trial
ould be the optimal means by which to formally evaluate
he encouraging signal we have observed for the additive
enefits of combination therapy.
linical implications. We found that in patients with
TEMI treated with fibrinolytic therapy and aspirin,
NOX significantly and comparably reduced the rate of
ACE, both in patients who were and were not treated
ith clopidogrel. The absolute excess of TIMI major
leeding seen with ENOX over UFH was numerically but
ot significantly greater in patients who were treated with
lopidogrel compared with those who were not, and there
as no significant excess in intracranial hemorrhage regard-
ess of clopidogrel use. The net clinical benefit of ENOX
ver UFH was quite similar in patients, irrespective of
oncomitant treatment with clopidogrel. Viewing the total-
ty of data, the CLARITY-TIMI 28 trial (4), the
OMMIT/CCS-2 trial (5), and now the ExTRACT-
IMI 25 trial suggest that the combination of a fibrinolytic,
spirin, clopidogrel, and ENOX offers an attractive phar-
acologic reperfusion strategy for patients presenting with
TEMI.
eprint requests and correspondence: Dr. Elliott M. Antman,
IMI Study Group, 350 Longwood Avenue, Boston, Massachu-
etts 02115. E-mail: eantman@rics.bwh.harvard.edu.
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